REPUBLIC HC(08357) issued a profit warning, expecting a net loss of approximately 3.7 million Singapore dollars in the fiscal year 2025 compared to the previous year.
HC(08357) announced that the Group expects its net loss for the fiscal year ending December 31, 2025 (during the period) to increase significantly by approximately 3.7 million Singapore dollars compared to the same period in 2024.
HC (08357) issued an announcement, expecting its net loss for the year ending December 31, 2025 (the period) to increase significantly by approximately 3.7 million Singapore dollars compared to the same period in 2024.
The increase in net loss attributable to shareholders is mainly due to the following factors: 1. Decrease in revenue due to intensified market competition, resulting in lower revenue for the group. The entry of new participants and the active expansion of existing competitors have significantly increased competitive pressure. Many participants have intensified their marketing efforts and launched new service projects, diverting some of the group's existing patient groups. 2. Macroeconomic pressures, changes in tariffs, and uncertainty in the economic environment have made patients more sensitive to prices, further affecting the group's revenue. 3. Regulatory developments: recent revisions to healthcare regulations have increased the group's compliance and operational burdens, resulting in a decline in overall financial performance. 4. Increase in operating expenses: (a) The group incurred exchange losses due to the significant depreciation of the US dollar and Hong Kong dollar against the Singapore dollar (the group's functional currency). (b) The group's education business in the Philippines and the expansion of medical business in the Chinese market incurred higher operating costs. These initiatives were not implemented in the previous year, and are currently in the early stages of investment and development. Therefore, they have not yet generated significant revenue contributions, and the related prior period costs have also contributed to the group's loss during the period.
Related Articles

Eternal Beauty (06883): Li Zhuoran appointed as Independent Non-Executive Director of the Company

TIANAN MEDICARE (00383) plans to offer a premium of approximately 15.79% to repurchase up to a maximum of 70 million shares. Resumption of trading on March 24th.

UJU HOLDING (01948) announces favorable profit growth, expecting annual net profit to increase by no less than approximately 30% year-on-year.
Eternal Beauty (06883): Li Zhuoran appointed as Independent Non-Executive Director of the Company

TIANAN MEDICARE (00383) plans to offer a premium of approximately 15.79% to repurchase up to a maximum of 70 million shares. Resumption of trading on March 24th.

UJU HOLDING (01948) announces favorable profit growth, expecting annual net profit to increase by no less than approximately 30% year-on-year.






